Conversations: Fireside Video Chats
The “Conversations” video series will feature virtual fireside chats with neuroscience experts who will discuss advances in the research and treatment of Alzheimer’s disease, dementia with Lewy bodies (DLB), and other age-related neurodegenerative conditions.
Please note, our podcast series does not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately.
Episode 7: Quantitative EEG: Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease
Featuring: | |
Anthony Caggiano, M.D., Ph.D. (moderator) Cognition Therapeutics |
Chief Medical Officer |
Willem de Haan, M.D., Ph.D. Alzheimer Center at Amsterdam University Medical Center |
Neurologist and Senior Researcher |
Philip Scheltens, M.D. EQT Life Sciences |
Partner and Head of Dementia Fund Former Director of the Alzheimer Center at Amsterdam University Medical Center |
Index: | |
0:00 | Introduction |
0:44 | Rationale for the SEQUEL Study Design |
2:10 | EEG in neurodegenerative diseases |
4:33 | Findings from SEQUEL |
9:52 | Key Takeaways |
Episode 6: Geographic Atrophy: New Strategies to Protect the Retina
Featuring: | |
Anthony Caggiano, M.D., Ph.D. Cognition Therapeutics |
Chief Medical Officer |
C. Gustavo De Moraes, M.D., Ph.D. moderator Columbia University and Ora (CRO) |
Associate Professor of Clinical Ophthalmology Chief Medical Officer |
Jeffrey S. Heier, M.D. Ophthalmic Consultants of Boston |
Director of the Vitreoretinal Service & Retina Research |
Peter K. Kaiser, M.D. Cleveland Clinic Lerner College of Medicine |
Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology |
Index: | |
0:00 | Introduction |
01:53 | Advances in Understanding of Geographic atrophy |
06:05 | Role of Complement in dry AMD |
10:50 | Evidence for sigma-2 modulation |
19:29 | The MAGNIFY Trial |
Episode 5: Exploring the Effects of CT1812 on Alzheimer’s Disease Processes: Proteomics and Pathways of Neurodegeneration​
Featuring: | |
Mary Hamby, Ph.D. Cognition Therapeutics |
Vice President of Research |
Charlotte Teunissen, Ph.D. moderator Amsterdam University Medical Center |
Professor of Clinical Neurochemistry |
Nicholas Seyfried, Ph.D. Emory University School of Medicine |
Professor of Biochemistry and Neurology Director of the Emory Integrated Proteomics Core |
Henrik Zetterberg, MD, Ph.D. Gothenburg University |
Professor of Neuroscience Group Leader of the UK Dementia Research Institute |
Index: | |
0:00 | Introduction |
01:53 | Utility of Proteomic Analysis in Alzheimer’s |
03:20 | Review of Proteomics Findings from AD/PD 2023 |
08:36 | Key Learnings |